UB BEP-supported pharmaceutical spinout POP Biotechnologies has been awarded a $2.46M grant by the National Institutes of Health (NIH) to pursue development of a “mosaic” active immunotherapy against Alzheimer’s disease.
Under the Phase II Small Business Technology Transfer (STTR) NIH grant, POP BIO will scale, characterize and validate the immunotherapy candidate with the goal of advancing toward human trials.
Read the full press release.